Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm

Cancer Family

Malignant Neoplasm

CI-CAN-00000025CAExplore in graph →

20,116 active trials259 approved drugs3,741 evidence items

NCIt: C9305
OncoTree: MT
DOID: 162
UMLS CUI: C0006826

Overview
Statistics
Survival
Genomics442
Variants & evidence3741
Drugs424
Trials90685
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,349)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 4,051–4,075 of 4,349 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
· Mol Oncol · 2013 · PMID 23415752 · validated civic_curation pubmed
Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
· PLoS One · 2017 · PMID 28672024 · validated civic_curation pubmed
Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.
· Blood · 2012 · PMID 23175662 · validated civic_curation pubmed
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
· Clin Cancer Res · 2018 · PMID 29588308 · validated civic_curation pubmed
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
· Cell · 2016 · PMID 27667683 · validated civic_curation pubmed
FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
· Clin Cancer Res · 2017 · PMID 28637688 · validated civic_curation pubmed
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
· Clin Cancer Res · 2022 · PMID 34593528 · validated civic_curation pubmed

Showing 4,051–4,075 of 4,349 publications

← Previous
1
…
162
163
164
…
174
Next →

Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

· Clin Cancer Res · 2014 · PMID 24963049 · validated civic_curation pubmed

Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer.

· Cell Death Discov · 2024 · PMID 38461159 · validated civic_curation pubmed

Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway.

· Cell Death Dis · 2021 · PMID 34247201 · validated civic_curation pubmed

Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.

· Nat Genet · 2025 · PMID 41361008 · validated civic_curation pubmed

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

· Cancer Cell · 2010 · PMID 20609353 · validated civic_curation pubmed

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.

· PLoS One · 2015 · PMID 26709701 · validated civic_curation pubmed

In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.

· Anticancer Res · 2015 · PMID 25550549 · validated civic_curation pubmed

Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.

· Melanoma Res · 2014 · PMID 24950457 · validated civic_curation pubmed

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

· Blood · 2006 · PMID 16690963 · validated civic_curation pubmed

Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.

· Mol Cancer Ther · 2013 · PMID 24140933 · validated civic_curation pubmed

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

· N Engl J Med · 2012 · PMID 22931316 · validated civic_curation pubmed

Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.

· Anticancer Drugs · 2016 · PMID 27276402 · validated civic_curation pubmed

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.

· PLoS One · 2016 · PMID 26751376 · validated civic_curation pubmed

Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.

· Oncotarget · 2016 · PMID 27612423 · validated civic_curation pubmed

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

· Sci Signal · 2010 · PMID 21098728 · validated civic_curation pubmed

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

· Clin Cancer Res · 2008 · PMID 18927303 · validated civic_curation pubmed

Targeting Akt3 signaling in triple-negative breast cancer.

· Cancer Res · 2014 · PMID 24335962 · validated civic_curation pubmed

The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

· Mol Cancer Ther · 2012 · PMID 22302096 · validated civic_curation pubmed